| Name | Celadon Pharmaceuticals |
|---|---|
| Epic | CEL |
| Isin | GB00BDQYGP38 |
| Industry | Open End and Miscellaneous Investment Vehicles |
| Latest share price | 22.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £15.15 | Debt ratio | n/a |
| Shares in issue | 68.85 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | n/a |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -11.5 | 52-week high / low | 12.50p / 117.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Celadon Pharmaceuticals |
|---|---|
| Address | 32-33 Cowcross Street, London, England, United Kingdom, EC1M 6DF |
| Telephone | +44 (0)207 4407 500 |
| Website | http://celadonpharma.com/ |
| Director | Position |
|---|---|
| Mr James Short | CEO |
| Mr Jonathan Turner | CFO |
| Mr I Alexander Anton | Non-Executive Chairman |
| Mr Robert Barr | Senior Independent Non-Executive Director |
| Mr Liz Shanahan | Independent Non-Executive Director |
| Mr David Firth | Independent Non-Executive Director |
| Dr Steven ("Steve") Hajioff | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 0.33 | 0.43 | 1.17 |
| Investments and other non-current assets | 0.22 | 0.22 | 0.2 |
| Total non-current assets | 6.72 | 6.92 | 4.67 |
| Inventory / work in progress | 0.06 | 0.02 | n/a |
| Trade and other receivables | 1.14 | 1.25 | 0.26 |
| Cash and equivalents | 1.26 | 5.06 | 3.82 |
| Other current assets and asset held for resale | 0.04 | n/a | n/a |
| Total of all assets | 9.22 | 13.25 | 8.76 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 0.95 | 1.2 | 8.58 |
| Long term liabilities | 5.09 | 5.02 | 4.57 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 6.04 | 6.21 | 13.16 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 3.18 | 7.04 | -4.4 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.64 | 0.62 | 0.08 |
| Minority interests | 0.02 | -0.64 | -0.26 |
| Retained earnings | -30.73 | -22.81 | -5.8 |
| Share premium account | 25.5 | 22.55 | 7.37 |
| Total equity | 3.18 | 7.04 | -4.4 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -5.93 | -5.38 | -2.71 |
| Pre-tax profit | -7.52 | -18.12 | -4.8 |